GC7101, an extract of Lonicera Flos, is a novel developing drug for reflux esophagitis and functional dyspepsia. However, the drug's exact pharmacological mechanism of action remains unclear. This study assessed the effects of GC7101 on gastrointestinal (GI) motor function.
Introduction
Functional dyspepsia (FD) is one of the most common gastrointestinal (GI) disorders, which is defined as occurrence of upper abdominal symptoms without organic causes. 1 The prevalence of FD defined according to strict criteria is about 5-12%. 2 The pathophysiology of FD is complex, with multiple factors implicated; however, abnormalities in GI motor function have been proposed as a major cause of FD. Abnormal gastric motility and visceral hypersensitivity are 2 major physiological abnormalities that cause FD. Other diverse factors such as genetic predisposition, a prior viral infection, stress, inflammation, Helicobacter pylori infection, abnormal secretion of gastric acid, psychological factors, diet and lifestyle could affect the pathogenesis of FD. 3 Although FD is a very common disorder, it is difficult to manage. Among the medications used to treat FD, prokinetics have shown efficacy in meta-analyses. 4 However, the reliability of these studies is very low and the adverse effects of previous prokinetics were serious. Therefore, new drugs for the treatment of FD including mosapride, itopride and acotinamide have been developed, which show improvements of GI motility without adverse cardiovascular events. 5 In this respect, the need of safer and more effective medications for the treatment of FD has increased. Thus, several herbal medicines were assessed for their potential to treat FD. 6 For example, DA-9701, an extract from 2 herbs (Pharbitis Semen and Corydalis Tuber) has been reported to accelerate gastric emptying in normal rats and restore delayed emptying. DA-9701 also increased GI transit in controls and delayed gastric emptying models induced by laparotomy or atropine. 7 In addition, Kim et al 8 showed that DA-9701 improved gastric accommodation by increasing the postprandial gastric volume in conscious dogs. At least 44 herbal products have been recommended for treatment of FD. 6 A large number of herbal medicine clinical trials showed that patients receiving peppermint and caraway had improved symptoms by 60-95%.
9
GC7101 is a potential prokinetic agent which was obtained from extracts of Lonicera Flos (LF). It is a widely used herbal medication in China and is known to have latent-heat-clearing, antipyretic, antioxidant and anti-inflammatory actions. 10 Ku et al 11 reported that the antioxidant properties of LF were effective in gastroesophageal reflux disease. They found that LF combated oxidative stress and free radical damage in esophageal and gastric mucosa in rat models. 11 In addition, they found that LF promoted gastric motor function (unpublished data). There are no previous reports on the effects of LF on GI motor function. Therefore, we aimed to investigate the prokinetic effect of GC7101 on GI contraction and transit and to validate which mechanisms GC7101 exerts through ex vivo.
M aterials and M ethods
Preparation of Animals 
Drugs
The following drugs and chemicals were used; charcoal (Sigma, St. Louis, MO, USA), barium sulfate (Tae Joon Pharmaceuticals, Seoul, Korea), GC7101 (Green cross Corp, Yongin, Korea), atropine and dopamine (Sigma, St. Louis, MO, USA), and GR113808 (Tocris, Ellisville, MO, USA). They were freshly made for every experiment by dissolving each compound in isotonic sodium chloride solution.
Experimental Design: The Effects of GC7101 on Antral Circular Muscle Contraction
Antral circular muscle was removed and cut into 3-mm wide and 10-mm long fragments and the lumen flushed clean using Krebs-Henseleit (K-H) solution which was maintained at 37 o C, pH 7.4 and saturated with 95% O 2 and 5% CO 2 in a chamber. The circular muscle was fixed and connected to independent tension transducers (BIOPAC TSD 105; BIOPAC Systems, Inc., Santa Barbara, CA, USA). The preparation was set up and allowed to equilibrate for at least 60 minutes after 1 g resting tension. Circular muscle activity was quantified by means of a computerized integration procedure (BIOPAC MP 100; BIOPAC Systems, Inc.). GC7101 (0.01-10 mg mL ) was added to the bath solution for 5 minutes without washing between successive changes in concentration. Drugs including GC7101, atropine, dopamine and GR113808, a selective 5-hydroxytrypt- 
GR 113808 1 mg kg −1 via orogastric cannula. After 30 minutes, GC7101 was administered via orogastric cannula, followed by 2.5 mL of a charcoal mixture after another 30 minute wait. The charcoal mixture consisted of charcoal, barium, and normal saline in a 1:2:6 ratio. The guinea pigs were sacrificed by blow to the occipital region and severing the carotid arteries. The abdomens were opened and the intestines were removed from the pyloric junction to the ileocecal valve. Upper GI transit was evaluated as the migration of charcoal mixture from the pylorus to the most distal point of migration, and expressed as a percentage (%) of charcoal migration (cm) to the length of total small intestine (cm) 5 minutes after injection of the charcoal mixture.
Statistical Methods
Results for each variable were expressed as percentage of control levels. Statistical analysis was performed using repeated measures ANOVA with post hoc comparison or the Mann-Whitney U test. In all tests, statistical significance was assigned if P ＜ 0.05 based on the mean. Values are means with standard error. All data were analyzed using SPSS version 12.0 for Windows software (SPSS Inc., Chicago, IL, USA).
Results

Effects of GC7101 on Contraction of Stomach Antral Muscle
The amplitude of circular muscle contraction increased in a dose dependent manner from 0.1 to 5 mg mL −1 (except 10 mg mL −1 ) GC7101. The maximal amplitude of the circular muscle contractions were 221.4 ± 49.7%, 315.7 ± 76.4%, 338.5 ± 80.2%, 396.8 ± 89.2% and 324.9 ± 94.2% in the presence of 0.1, 0.5, 1, 5 and 10 mg mL −1 GC7101, respectively. The maximal amplitude of the circular muscle contraction was induced by 5 mg mL −1 GC7101 (Fig. 1A) . The AUC of the circular muscle contraction also increased in a dose dependent manner with 0.1 to 5 mg mL −1 (except 10 mg mL
) GC7101. The AUC of the circular muscle contractions were 190.2 ± 32.4%, 282.8 ± 56.3%, 312.8 ± 57.9%, 373.3 ± 58.4% and 339.2 ± 84.4% in the presence of 0.1, 0.5, 1, 5 and 10 mg mL −1 GC7101, respectively. The maximal AUC of the circular muscle contraction was induced by 5 mg mL −1 GC7101 (Fig. 1B) .
Addition of 10 −6 M atropine, 10 −8 M dopamine, or 10 −7 M GR 113808 to GC7101 5 mg mL −1 decreased the amplitude compared to GC7101 alone (228.4 ± 48.5% vs. 171.5 ± 38.1%, P = 0.046; 228.4 ± 40.3% vs. 202.6 ± 36.8%, P = 0.043; 157.6 ± 26.3% vs. 141.3 ± 24.7%, P = 0.043; respectively) (Fig. 2) .
Effects of GC7101 on the Transit of Charcoal
The average charcoal transit was 35.1 ± 5.6% in the control group. The percentage (%) of the migration length (cm) of charcoal to total small intestine (cm) was 46.4 ± 7.9%, 55.9 ± 4.1% and 20.1 ± 6.8% in 25 mg kg −1 , 50 mg kg −1 and 100 mg kg
GC7101, respectively (P = 0.002). In normal guinea pigs, GC7101 accelerated GI transit of charcoal in a dose dependent manner except the 100 mg kg −1 dose. The maximal charcoal transit was induced by 50 mg kg −1 GC7101 (P = 0.030 compared to the control). However, the charcoal transit slightly decreased with 100 mg kg −1 GC7101 (Fig. 3) . Subsequently, we used the delayed model of GI transit to assess whether GC7101 is able to reverse abnormally delayed GI transit. Delayed charcoal transit after administration of atropine 0.1 mg kg
, dopamine at a dose of 50 mg kg −1 (Fig. 4) . These results showed that GC7101 not only accelerated GI transit in normal conditions, but furthermore restored delayed GI transit induced by atropine, dopamine or GR113808.
Discussion
FD is a chronic and highly prevalent GI disorder that imposes a large amount of healthcare cost on patients. Therefore, many studies are ongoing to identify therapeutic agents for FD. Prokinetics are known to be helpful for relieving the symptoms of FD. However, their application is very limited due to several factors including ineffectiveness and potentially fatal side effects. As the demands of more safe and effective medications for FD increased, several herbal medicines have been evaluated for their potential use. GC7101 is an extract of LF which is a widely prescribed herbal medicine in China. However, the pharmacological effects of LF on GI motor function have not been studied yet. There was one report that application of the Chinese herbal recipe composed of multiple plants and roots including LF could effectively promote postoperative recovery of GI motility. 12 For the first time, we showed that GC7101 has effects on GI motor function assessed by gastric antral contraction and GI transit. It implies that GC7101 is a potential candidate to treat FD with delayed gastric emptying. GI transit and gastric antral contraction are well established models to assess prokinetic effects. Atropine has inhibitory effects on GI motility by acting as a competitive antagonist of the acetylcholine receptors. Dopamine and GR 113808 also delay GI motility through dopamine receptors and antagonism of 5-HT 4 -receptors, respectively. Dopamine decreases motility of the GI tract, whereas dopamine antagonists increase peristaltic contraction of the esophageal muscles and improve GI motor activity. 13 Selective 5-HT 4 receptor agonists has been shown to enhance gastric accommodation and accelerate gastric emptying and GI transit. 14 GC7101 could restore the delayed GI transit caused by atropine, dopamine, or GR113808. The increased contraction by GC7101 was inhibited by atropine, dopamine, or GR113808. Taken together, GC7101 enhances GI motor function by acting on cholinergic, antidopaminergic, and serotonergic mechanisms. These results showed that GC7101 could enhance GI motility both in normal or abnormal conditions and identify a possible novel therapeutic agent of FD.
In conclusion, GC7101 which is an extract from LF, exerts a gastric prokinetic effect in guinea pigs through multiple mechanisms including cholinergic, antidopaminergic and serotonergic mechanism. Further studies are definitely warranted to prove the therapeutic use of GC7101 in FD through highly qualified and controlled clinical trials.
